Phase 2 Trial Testing Darinaparsin Completes Enrollment of Asian Patients with Relapsed or Refractory PTCL
News
A Phase 2 clinical trial assessing Solasia Pharma’s lead candidate darinaparsin as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL) in Asian patients has reached its target enrollment, ... Read more